ESMO 2025, CStone Pharmaceuticals to disclose CS5001 ADC updated study design for the first time

CAR-T Digest - August 2020

28 July 2025: ESMO 2025, CStone Pharmaceuticals to disclose CS5001 ADC updated study design for the first time

The Phase 1 global, multicenter trial of CS5001 is currently ongoing in the U.S., Australia, and China, and its updated study design will be presented for the first time at ESMO 2025
CS5001 has shown clinical efficacy in both lymphoma and solid tumors, making it one of the top two ROR1 ADCs in global clinical development
Preclinical studies of CS5001 demonstrated complete tumor inhibition, favorable pharmacokinetics, and a promising safety profile across various tumor models
CS5001, originally developed by LCB and ABL Bio, is licensed globally (excluding Korea) to CStone Pharmaceuticals, which uses targeted conjugation technology to ensure a consistent drug-to-antibody ratio and scalable manufacturing